Coronary Heart Disease
Conditions
Brief summary
The objective of this pilot study is to compare the PFS-eluting stent (ISAR Rapa G1) with the PPS-eluting stent (Cypher®) regarding uncovered stent strut segments at 5 years.
Detailed description
The mid-term efficacy of drug-eluting stents has been well-established, but there is an ongoing debate on the potential of an increased incidence of late stent thrombosis, particularly after discontinuation of thienopyridine therapy, as well as of delayed onset of restenosis or catch-up phenomenon with permanent polymer-based DES. The extent of strut coverage with reduction of exposed thrombogenic material has been shown to be associated with the inflammatory reaction grade and with the incidence of stent thrombosis. The optical coherence tomography (OCT) is an intravascular imaging modality based on light. The principle is similar to intravascular ultrasound, but due to the much shorter wave length of light, it offers a much better resolution up to 10µm, enabling the exact determination of strut coverage, neointimal thickness, vessel size, presence of dissections, and even the presence of inflammation. Patients who received a polymer-free or a permanent-polymer sirolimus-eluting stent about 5 years ago without in-segment intervention since, will be evaluated by OCT regarding the healing pattern and the late lumen loss of the stent.
Interventions
DEVICESirolimus-Permanent-Polymer Eluting Stent
due randomization sirolimus-permanent-polymer eluting stent was implanted
DEVICESirolimus-Polymer-free Eluting Stent
due randomization sirolimus-polymer-free eluting stent was implanted
Sponsors
Deutsches Herzzentrum Muenchen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients older than age 18 with with previous implantation of polymer-free or permanent-polymer sirolimus-eluting stents 5 years ago due to ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% stenosis located in native coronary vessels. * Written, informed consent by the patient or her/his legally-authorized representative for participation in the study and assessment by OCT. * In women with childbearing potential a negative pregnancy test is mandatory.
Exclusion criteria
* Intervention in the segment of the study stent after the index procedure * Target lesion located in the left main trunk. * In-stent restenosis with difficulty to pass the OCT device * Acute myocardial infarction * Known allergy to the study medications: Sirolimus, rapamycin, probucol or stainless steel. * Pregnancy (present, suspected or planned) or positive pregnancy test. * Patient's inability to fully cooperate with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of stent strut coverage after 5 years assessed by OCT for each visible strut segment | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of malapposed strut assessed by OCT | 5 years |
| Percentage of uncovered malapposed struts assessed by OCT | 5 years |
| Morphologic differences of neointima between stents | 5 years |
| Late lumen loss at 5 years assessed by OCT | 5 years |
Countries
Germany
Contacts
Primary ContactJulinda Mehilli, MD
Backup ContactKlaus Tiroch, MD
Outcome results
None listed